BioXcel Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
BioXcel Therapeutics (BTAI) Misses Q3 EPS by 27c
November 12, 2020 7:06 AM ESTBioXcel Therapeutics (NASDAQ: BTAI) reported Q3 EPS of ($1.07), $0.27 worse than the analyst estimate of ($0.80).
Building on the successful data readout from the Phase 3 SERENITY trials earlier this year, we have continued to make substantial progress with BXCL501s development as a treatment for agitation across neuropsychiatric conditions, stated Vimal Mehta, Chief Executive Officer of BTI.... More
